Autobio 安图生物
China · Zhengzhou
alternative to Roche Diagnostics / Abbott Diagnostics
AutoLumo chemiluminescence immunoassay analyzers and reagents, microbiology systems (blood culture, Autof mass-spectrometry identification, susceptibility testing), plus biochemistry, coagulation, molecular and lab-automation lines. Overseas sales were 9% of 2025 revenue.
Why it fits
- In-Vitro Diagnostics
- Cost-effective
Regional alternatives
Product facts
- Segment
- In-Vitro Diagnostics
- Role
- Manufacturer
2025 results: revenue CNY 4.23B (-5.5%), overseas revenue CNY 384M (+35%).
Market authorizations
European Union
- CE marked (IVDR): Chemiluminescent microparticle immunoassays for autoimmune and thyroid markers (Class B/C)IVDR 779366 · BSI Group The Netherlands B.V. (2797) · decided 2023-12-12 · valid through 2028-12-11 Source (checked 2026-10)
Verified records only; absence here does not mean a product is unauthorized.
Company & market
- Parent company
- Autobio Diagnostics
- Registered
- Zhengzhou
- Listing
- A-share
- Ticker
- 603658.SS
- Market cap / val. (USD)
- ~$2.7 B
- Foreign-investable
- Yes